Mainz BioMed NV

Contributing Author

Recent Articles by Mainz BioMed NV

Mar-11	Mainz Biomed Announces Appointment of Robert Liscouski as Chairman of the Board of Directors GlobeNewswire
Feb-24	Mainz Biomed to Present at the Pancreatic Cancer Session at Digestive Disease Week, Demonstrating Effectiveness of mRNA Biomarkers in Blood Samples GlobeNewswire
Feb-17	Mainz Biomed Announces 6.0 USD Million Private Placement and Strategic Update GlobeNewswire
Jan-14	Mainz Biomed to Present Results of Pancreatic Cancer Verification Study at AACR 2026 Annual Meeting GlobeNewswire
Jan-05	Mainz Biomed Provides Review of 2025 Highlights GlobeNewswire
Dec-02	DoctorBox Adds Mainz Biomed's ColoAlert(R) to Its Portfolio GlobeNewswire
Nov-18	Mainz Biomed and OncoVanguard8 Enter into Agreement to bring ColoAlert to South America GlobeNewswire
Nov-12	Mainz Biomed Showcases Innovative Cancer Detection Solutions at MEDICA 2025 GlobeNewswire
Nov-10	Mainz Biomed to Attend the 38th Annual Meeting of the Gastroenterological Working Group of Rhineland-Palatinate (GARPS) GlobeNewswire
Oct-15	Mainz Biomed to Attend 2025 Maxim Growth Summit GlobeNewswire
Oct-08	Mainz Biomed Reports Topline Results from Feasibility Study of Biomarker Panel in Pancreatic Cancer Project GlobeNewswire
Sep-30	Mainz Biomed to Present the Future of Colorectal Cancer Screening at WEO CRC Screening Committee Meeting GlobeNewswire
Sep-23	Mainz Biomed Announces Commercial Launch of ColoAlert in Switzerland GlobeNewswire
Sep-02	Mainz Biomed Announces Registration of ColoAlert in the United Kingdom GlobeNewswire
Aug-13	Mainz Biomed Receives Swiss Regulatory Approval to Market ColoAlert GlobeNewswire
Aug-04	Mainz Biomed Announces Pricing of $3.0 Million Follow-On Offering of Ordinary Shares and Warrants GlobeNewswire
Jul-23	Mainz Biomed and CARE Conclude Cooperation Agreement for Joint Care Concept for Health Insurance Companies GlobeNewswire
Jul-15	Mainz Biomed Half Year 2025 Update: Accelerating FDA Pathway for NextGen Colorectal Cancer Screening and Expansion with Pancreatic Cancer Screening Acquisition GlobeNewswire
Jun-25	Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening Test GlobeNewswire
Jun-10	Mainz Biomed Initiates Feasibility Study of Biomarker Panel in Pancreatic Cancer Project GlobeNewswire
May-19	Mainz Biomed Announces Pricing of $4.0 Million Follow-On Offering of Ordinary Shares and Warrants GlobeNewswire
May-16	Mainz Biomed Announces Interim Read Out For Its eAArly DETECT 2 Clinical Study GlobeNewswire

Mainz BioMed NV

Recent Articles by Mainz BioMed NV

Upgrade your Finviz experience